Form 4: Haemonetics Corp Executive Josep Llorens Reports Share Transactions

Josep Llorens, EVP of Global Manufacturing at Haemonetics Corp, reports acquisition of shares from a performance share unit award and disposition of shares for tax obligations.

Summary

• Josep Llorens, EVP of Global Manufacturing at Haemonetics Corp, filed a Form 4 detailing changes in beneficial ownership.
• On May 28, 2024, Llorens acquired 14,140 shares of common stock from a performance share unit (PSU) award.
• These shares were earned based on Haemonetics' total shareholder return relative to the S&P MidCap 400 Index from May 18, 2021, to May 17, 2024.
• Also on May 28, 2024, Llorens disposed of 4,510 shares of common stock at $95.73 per share to cover tax obligations related to the vesting of the PSUs.
• Following these transactions, Llorens beneficially owns 30,940 shares of Haemonetics Corp common stock, including unvested restricted stock units (RSUs).

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document primarily reports routine transactions related to executive compensation. The PSU vesting suggests positive performance, but the tax-related sale is a standard occurrence.

Positives

• The acquisition of shares from the PSU award indicates that Haemonetics met certain performance criteria related to shareholder return.

Negatives

• The disposition of shares to cover tax obligations reduces Llorens' direct holdings in the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive compensation and ownership.

Key Dates